HIV-1 Tat protein promotes formation of more-processive elongation complexes
- PMID: 1756726
- PMCID: PMC453171
- DOI: 10.1002/j.1460-2075.1991.tb04997.x
HIV-1 Tat protein promotes formation of more-processive elongation complexes
Abstract
The Tat protein of HIV-1 trans-activates transcription in vitro in a cell-free extract of HeLa nuclei. Quantitative analysis of the efficiency of elongation revealed that a majority of the elongation complexes generated by the HIV-1 promoter were not highly processive and terminated within the first 500 nucleotides. Tat trans-activation of transcription from the HIV-1 promoter resulted from an increase in processive character of the elongation complexes. More specifically, the analysis suggests that there exist two classes of elongation complexes initiating from the HIV promoter: a less-processive form and a more-processive form. Addition of purified Tat protein was found to increase the abundance of the more-processive class of elongation complex. The purine nucleoside analog, 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB) inhibits transcription in this reaction by decreasing the efficiency of elongation. Surprisingly, stimulation of transcription elongation by Tat was preferentially inhibited by the addition of DRB.
Similar articles
-
Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.Gene Expr. 1992;2(4):391-407. Gene Expr. 1992. PMID: 1282057 Free PMC article.
-
DSIF and NELF interact with RNA polymerase II elongation complex and HIV-1 Tat stimulates P-TEFb-mediated phosphorylation of RNA polymerase II and DSIF during transcription elongation.J Biol Chem. 2001 Apr 20;276(16):12951-8. doi: 10.1074/jbc.M006130200. Epub 2000 Dec 8. J Biol Chem. 2001. PMID: 11112772
-
Stimulation of Tat-associated kinase-independent transcriptional elongation from the human immunodeficiency virus type-1 long terminal repeat by a cellular enhancer.EMBO J. 1999 Mar 1;18(5):1378-86. doi: 10.1093/emboj/18.5.1378. EMBO J. 1999. PMID: 10064603 Free PMC article.
-
HIV-1 Tat: coping with negative elongation factors.Curr Opin Immunol. 1999 Aug;11(4):460-5. doi: 10.1016/S0952-7915(99)80077-6. Curr Opin Immunol. 1999. PMID: 10448148 Review.
-
Tat and the HIV-1 promoter.Curr Opin Cell Biol. 1993 Jun;5(3):461-8. doi: 10.1016/0955-0674(93)90012-f. Curr Opin Cell Biol. 1993. PMID: 8352964 Review.
Cited by
-
Endogenous MCM7 microRNA cluster as a novel platform to multiplex small interfering and nucleolar RNAs for combinational HIV-1 gene therapy.Hum Gene Ther. 2012 Nov;23(11):1200-8. doi: 10.1089/hum.2012.011. Epub 2012 Sep 18. Hum Gene Ther. 2012. PMID: 22834872 Free PMC article.
-
Analysis of Tat transactivation of human immunodeficiency virus transcription in vitro.Gene Expr. 1992;2(4):391-407. Gene Expr. 1992. PMID: 1282057 Free PMC article.
-
Circular dichroism and molecular modeling yield a structure for the complex of human immunodeficiency virus type 1 trans-activation response RNA and the binding region of Tat, the trans-acting transcriptional activator.Proc Natl Acad Sci U S A. 1992 Oct 15;89(20):9734-8. doi: 10.1073/pnas.89.20.9734. Proc Natl Acad Sci U S A. 1992. PMID: 1409690 Free PMC article.
-
A nucleolar TAR decoy inhibitor of HIV-1 replication.Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14047-52. doi: 10.1073/pnas.212229599. Epub 2002 Oct 10. Proc Natl Acad Sci U S A. 2002. PMID: 12376617 Free PMC article.
-
Adenovirus E1A N-terminal amino acid sequence requirements for repression of transcription in vitro and in vivo correlate with those required for E1A interference with TBP-TATA complex formation.J Virol. 2002 Feb;76(3):1461-74. doi: 10.1128/jvi.76.3.1461-1474.2002. J Virol. 2002. PMID: 11773419 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases